Company profile / HIKAL

Hikal

Other · 2 quarters tracked · source-linked performance and management context.

Research layer active
WatchCredibility 0/100Latest record q4-fy26

Latest revenue

₹519.4 Cr

verified financial record

Quarters tracked

2

source records in the directory

Delivery assessment

0

Across 2 tracked commitments: 0 delivered, 2 missed.

Call date

2026-04-??

latest available source date

Signal trajectory

2 actual quarters
EBITDA (₹ Cr)PositiveWatchNegative
2 actual records
Actual quarterly EBITDA (₹ Cr) trajectoryReported values plotted by quarter. Hover or focus a point for its quarter, value, and source sentiment.Q3 FY26: 83 · Positive source sentiment · 2026-02-09Q3 FY26Q4 FY26: 105 · Watch source sentiment · 2026-04-??Q4 FY2610583
Values are taken from the available verified source records; sentiment color is a separate source-read indicator.

Current read

0/100

Across 2 tracked commitments: 0 delivered, 2 missed.

Latest source read

What changed this quarter?

Open quarter read

Hikal's Q4 FY26 revenue stood at 519 crores with EBITDA margins improving to 20.3%, driven by recovery in crop protection and pharma demand. Full-year revenue was 1,713 crores with EBITDA margin of 12.9%. Pharma division faced headwinds from USFDA warning letter at Bangalore site, slowing shipments and new CDMO growth. Crop protection saw volume recovery as inventory destocking ends. Management expects FY27 to be a transition year with growth returning, but refrained from specific guidance due to geopolitical uncertainty. Key risk: USFDA resolution timeline and raw material cost pass-through lag.

Colored figures compare against the previous available record. Hover or focus one for the comparison.

Signal

Watch

Revenue

₹519.4 Cr

Source date

2026-04-??

Across the record

Quarter history.

2 source records

History modules

Follow the numbers and themes.

Revenue history PAT history Margin trend Guidance tracker Bear-case history Language trends FY26 summary